Tuberculosis, a deadly infectious disease, has long been a challenge to eradicate due to the bacterium's remarkable ability to withstand the human body's harsh conditions and immune attacks. Researchers are now turning their attention to the bacterium's stress-response machinery, particularly the proteasome, as a potential avenue for new treatments. A recent study by the University of Guelph, published in Nature Communications, sheds light on the proteasome's inner workings and the role of the Bacterial proteasome activator (Bpa) in clearing damaged proteins. This discovery could pave the way for innovative antibiotics that target the stress-response machinery rather than killing the bacterium outright.
The proteasome, akin to a recycling center, plays a crucial role in breaking down damaged proteins to prevent interference with essential cellular processes. Bpa, the sorting gate of this recycling center, is responsible for selecting proteins for destruction. However, the exact mechanism by which Bpa identifies its targets has been elusive due to the instability of the proteins it targets, making them challenging for researchers to study.
To overcome this hurdle, PhD candidate Bradley Davis employed a creative approach. He engineered a model Bpa substrate using a piece of human protein and utilized Nuclear Magnetic Resonance (NMR) spectroscopy to map how Bpa recognizes target proteins and reorganizes into its active form in response to stress. The findings revealed that under warmer, more stressful conditions, Bpa assembles from smaller inactive units into a ring-shaped structure, enhancing its ability to grab proteins and send them to the proteasome for breakdown.
This shape-shifting ability of Bpa is believed to be vital for the bacterium's survival within the human body. Bpa identifies target proteins by recognizing exposed "greasy" patches, which are typically found inside healthy proteins but become exposed when proteins are damaged or stressed. This knowledge provides valuable insights for drug designers, enabling them to devise strategies to fool or block Bpa.
The implications of this research are far-reaching for tuberculosis treatment. Dr. Siavash Vahidi, an associate professor and senior author of the study, suggests that future drugs could target Bpa in an inactive state, disrupting the bacterium's ability to handle stress in the human body and making it more susceptible to the immune system. This approach could potentially reduce the reliance on prolonged antibiotic treatments, which are often complicated by the bacteria's growing resistance to available antibiotics.
The collaborative effort between the Vahidi lab, Dr. Lewis Kay's lab at the University of Toronto, and scientists at Waters Corporation played a pivotal role in this breakthrough. By combining advanced techniques and state-of-the-art mass spectrometry instrumentation, the team was able to answer complex questions that would have been impossible to address independently.
In conclusion, this research offers a promising avenue for developing new tuberculosis treatments that target the stress-response machinery. By understanding Bpa's role in protein selection and its response to stress, scientists are one step closer to creating innovative antibiotics that can disrupt the bacterium's ability to cope with the immune system, ultimately leading to more effective and sustainable tuberculosis management.
